Welcome to NDF Research
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog
US patents related to the Life Sciences sector in Australia and New Zealand and granted in 2016
Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (3 October 2017)

The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.

Australian grants

Here are the 111 US patents relevant to Australia's Life Sciences sector that were granted in 2016, for an issuance rate of 2.1  per week:
  • US Patent 9,527,908, ​Modified variable domain molecules and methods for producing them, Garvan Institute of Medical Research, 27 December 2016
  • US Patent 9,526,734, ​​Formulation of meloxicam, iCeutica, 27 December 2016
  • US Patent 9,522,214, ​Viscous haemostatic compositions and method of treatment, Eupharma, 20 December 2016
  • US Patent 9,518,127, Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses, CSL Ltd, 13 December 2016
  • US Patent 9,518,109, ​Prevention, treatment and diagnosis of P. gingivalis infection, Oral Health Australia Pty Ltd, 13 December 2016
  • US Patent 9,518,089, ​Metallothionein-derived peptide fragments, University of Tasmania, 13 December 2016
  • US Patent 9,511,080, Okadaella gastrococcus and cancer Takayuki Okada, 6 December 2016
  • US Patent 9,511,031, ​Controlled release doxycycline, Mayne Pharma, 6 December 2016
  • US Patent 9,511,017, ​Method and composition for use in preparation of a patient for surgery, Novapharm Research (Australia) Pty Ltd, 6 December 2016
  • US Patent 9,498,525, ​Treatment or prophylaxis of asthma, Hunter Immunology, 22 November 2016
  • US Patent 9,492,552, ​Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative, Jurox Pty Ltd, 15 November 2016
  • US Patent 9,492,547, ​Polymorphic form of inulin and uses thereof, Vaxine Pty Ltd, 15 November 2016
  • US Patent 9,486,497, ​Treatment of immunocompromised conditions, University of Queensland, 8 November 2016
  • US Patent 9,480,717, ​Composition of whey growth factor extract for reducing muscle inflammation, Murray Goulburn Co-Operative, 1 November 2016
  • US Patent 9,474,789, ​​Methods and compositions for promoting organ growth and development, Kintan Pty Ltd, 25 October 2016
  • US Patent 9,474,270, ​Methods and compositions for controlling pests, Bioprospect and University of Western Sydney, 4 October 2016
  • US Patent 9,458,093, ​Compositions for the treatment of hypertension and/or fibrosis​​, Vectus Biosystems (ASX: VBS), 4 October 2016
  • US Patent 9,457,107, Cage amine ligands for metallo-radiopharmaceuticals, ​University of Melbourne,  4 October 2016
  • US Patent 9,457,062, Chaperonin 10-induced immunomodulation, ​​ Invion (ASX: IVX),  4 October 2016
  • US Patent 9,452,148, Insulin sensitisers and methods of treatment, Verva Pharmaceuticals, 27 September 2016
  • US Patent 9,452,037, Delivery of oral care products, OBJ Ltd (ASX: OBJ), 27 September 2016
  • US Patent 9,447,080, Viral polymerase inhibitors,  Biota, 20 September 2016
  • US Patent 9,446,057, Controlled release doxycycline,  Mayne Pharma (ASX: MYX), 20 September 2016
  • US Patent 9,441,239, Methods and means for obtaining modified phenotypes, Commonwealth Scientific and Industrial Research Organisation, 13 September 2016
  • US Patent 9,440,926, Antiviral compounds and methods, Biotron (ASX: BIT), 13 September 2016
  • US Patent 9,439,946, Reconstituted high density lipoprotein formulation and production method thereof, CSL Ltd (ASX: CSL), 13 September 2016
  • US Patent 9,433,805, Method for dermal regeneration by administering an ether cross-linked glucomannan/hyaluronic acid composition, Ultraceuticals, 6 September 2016
  • US Patent 9,428,587, Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof, Biosceptre International, 30 August 2016
  • US Patent 9,427,443, Anaesthetic composition, Jurox Pty Ltd, 30 August 2016
  • US Patent 9,422,522, Method of producing adipocytes from fibroblast cells, Regenertech Pty Ltd (Dr Vishal Bhasin), 23 August 2016
  • US Patent 9,421,205, FAK inhibitors, Cancer Therapeutics CRC , 23 August 2016
  • US Patent 9,415,063, Treatment of neurological disorders, Velacor Therapeutics, 16 August 2016
  • US Patent 9,408,919, Biodegradable polymer-bioactive moiety conjugates​​, PolyActiva Pty Ltd, 9 August 2016
  • US Patent 9,408,824, Compositions and products containing S-equol, and methods for their making​​, Sanitarium with Cincinnati Children's Hospital​ (United States), 9 August 2016
  • US Patent 9,402,902, Composition and method for the treatment and prevention of enteric bacterial infections​, Immuron (ASX: IMC), 2 August 2016
  • US Patent 9,402,896, Method of inducing tolerance to an allergen​​, Murdoch Childrens Research Institute, 2 August 2016
  • US Patent 9,394,353, Method for improving the stability of purified factor VIII after reconstitution​​, CSL Ltd (ASX: CSL), 19 July 2016
  • US Patent 9,393,287, Methods and compositions for promoting organ development​, Kintan Pty Ltd, 19 July 2016
  • US Patent 9,393,274, Control of sucking lice​​, Dudley Pinnock and David Cooper, 19 July 2016
  • US Patent 9,387,218, Composition for the treatment of inflammatory and immune disorders​​, Eaglepharma Pty Ltd (Paul Turner), 12 July 2016
  • US Patent 9,387,213, Small molecules inhibiting oncoprotein Myc​​, Panacela Labs (part owned by Children's Cancer Institute Australia), 12 July 2016
  • US Patent 9,381,262, Methods for radiolabeling synthetic polymers, Australian National University, 5 July 2016
  • US Patent 9,381,240, Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors, Queensland Department of Agriculture and Fisheries with Meat & Livestock Australia, 5 July 2016
  • US Patent 9,376,682, Method of treating pulmonary disease by administering an antibody to G-CSF, CSL Ltd (ASX: CSL), 28 June 2016
  • US Patent 9,371,530, Modulation of growth hormone receptor expression and insulin-like growth factor expression, Antisense Therapeutics (ASX: ANP), 21 June 2016
  • US Patent 9,365,829, Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof, University of Technology, Sydney, 14 June 2016
  • US Patent 9,365,650, Single chain antibodies that specifically bind to the activated state of the platelet integrin receptor GP IIb/IIIa, Baker IDI Heart and Diabetes Institute, 14 June 2016
  • US Patent 9,364,570, Functionalisation of cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 14 June 2016
  • US Patent 9,364,534, Treatment of neurological conditions, CSL Ltd (ASX: CSL), 14 June 2016
  • US Patent 9,364,016, Extracts derived from sugar cane and a process for their manufacture, The Product Makers (Australia) Pty Ltd, 14 June 2016
  • US Patent 9,359,422, Single chain relaxin polypeptides, University of Queensland with Florey Institute of Neuroscience and Mental Health, 7 June 2016
  • US Patent 9,359,377, Substituted imidazo[1,2-a]imidazo[4',5':4,5]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections, Biota, 7 June 2016
  • US Patent 9,358,247, Methods and compositions for promoting activity of anti-cancer therapies, ORIL, 7 June 2016
  • US Patent 9,357,783, Methods and compositions for controlling ectoparasites, Hatchtech Pty Ltd, 7 June 2016
  • US Patent 9,353,152, Induction of the mitochondrial permeability transition, University of New South Wales, 31 May 2016
  • US Patent 9,352,038, Treatment of neurological conditions, ​CSL Ltd (ASX: CSL), 31 May 2016
  • US Patent 9,352,034, Methods of treating pain using an antibody specific for GM-CSF, University of Melbourne, 31 May 2016
  • US Patent 9,351,977, Methods of reducing mammographic breast density and/or breast cancer risk, Chavah Pty Ltd , 31 May 2016
  • US Patent 9,346,842, Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors, Bionomics (ASX: BNO), 24 May 2016
  • US Patent 9,345,911,  Methods of inducing melanogenesis in a subject, Clinuvel Pharmaceuticals (ASX: CUV), 24 May 2016
  • US Patent 9,345,667, Particles having hydrophobic material therein, ​Australian Nuclear Science & Technology Organisation, 24 May 2016
  • US Patent 9,340,622, Synthetic immunogen useful for generating long lasting immunity and protection against pathogens, University of Melbourne with the ​Council of Scientific and Industrial Research (India), 17 May 2016
  • US Patent 9,340,583, VIP fragments and methods of use, ​Vectus Biosystems (ASX: VBS), 17 May 2016
  • US Patent 9,340,517, Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor,  Mimetica Pty Ltd, 17 May 2016
  • US Patent 9,328,164, Anti-nerve growth factor antibodies and methods of preparing and using the same, NVIP, 3 May 2016
  • US Patent 9,328,155, Peptides for inducing antibodies to a non-functional P2X7 receptor, BioSceptre, 3 May 2016
  • US Patent 9,326,539, Compositions comprising dietary fat complexers and methods for their use​,  Soho Flordis International, 3 May 2016
  • US Patent 9,320,755, Therapeutic and diagnostic molecules, Centenary Institute with University of Sydney and the Wenkart Foundation, 26 April 2016
  • US Patent 9,315,581, Immuno-conjugates and methods for producing them, Avipep Pty Ltd, 19 April 2016
  • US Patent 9,314,527, Transdermal delivery patch, Phosphagenics (ASX: POH), 19 April 2016
  • US Patent 9,314,450, Combination therapy, Dimerix (ASX: DXB), 19 April 2016
  • US Patent 9,308,193, Kinase inhibitors for the treatment of cancer, ​PharmAust (ASX: PAA), 12 April 2016
  • US Patent 9,303,026, Antiviral agents, Biota, 5 April 2016
  • US Patent 9,302,993, 8-hydroxy quinoline derivatives, Prana Biotechnology (ASX: PBT), 5 April 2016
  • US Patent 9,299,476, Polymeric material, University of New South Wales, 29 March 2016
  • US Patent 9,295,654, Layered nanoparticles, ​Australian Nuclear Science & Technology Organisation, 29 March 2016
  • US Patent 9,295,652, Controlled release doxycycline, Mayne Pharma (ASX: MYX), 29 March 2016
  • US Patent 9,295,628, Stabilized calcium phosphate complexes, University of Melbourne, 29 March 2016
  • US Patent 9,290,577, Immuno-conjugates and methods for producing them, Avipep Pty Ltd, 22 March 2016
  • US Patent 9,289,586, Spreading implement, Acrux (ASX: ACR), 22 March 2016
  • US Patent 9,289,410, Tiglien-3-one derivatives, QBiotics, 22 March 2016
  • US Patent 9,289,381, Stabilization and storage of biological pharmaceutical compositions, Monash University with University of North Carolina at Charlotte (US) and Charlotte-Mecklenburg Hospital Authority (US) , 22 March 2016
  • US Patent 9,283,365, Patch production, University of Queensland, 15 March 2016
  • US Patent 9,283,291, Methods for radiolabeling macromolecules, Australian National University, 15 March 2016
  • US Patent 9,283,212, Pharmaceutical preparation and delivery system, Palmaya Pty Ltd (​Dr George O'Neil), 15 March 2016
  • US Patent 9,278,134, Dual functioning ionic liquids and salts thereof, Monash University with​ University of Alabama (US) and Queen's University Belfast (UK), 8 March 2016
  • US Patent 9,273,125, Human monoclonal antibody having fat-reducing effect, Patrys (ASX: PAB), 1 March 2016
  • US Patent 9,272,046, Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma (ASX: MYX), 1 March 2016
  • US Patent 9,271,982, Animal feed supplement comprising ractopamine and caffeine, Rivalea, 1 March 2016
  • US Patent 9,271,503, Control of insect pests, Innovate Ag, 1 March 2016
  • US Patent 9,268,908, Computer systems for treating diseases, Biotempus, 23 February 2016
  • US Patent 9,266,864, VEGFR3 inhibitors, Cancer Therapeutics CRC, 23 February 2016
  • US Patent 9,265,817, PAT-LM1 epitopes and methods for using same, ​Patrys (ASX: PAB), 23 February 2016
  • US Patent 9,265,726, Foamable suspension gel, Stiefel Research Australia, 23 February 2016
  • US Patent 9,265,249, Dispersants in high-electrolyte solutions, Huntsman Corporation Australia, 23 February 2016
  • US Patent 9,260,691, Methods relating to an attenuated mycoplasma, Bioproperties Pty Ltd, 16 February 2016
  • US Patent 9,260,526,  Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy, Opthea (ASX: OPT), 16 February 2016
  • US Patent 9,254,322, Compositions comprising E-selectin antagonists and uses therefor, University of Queensland, 9 February 2016
  • US Patent 9,254,288, Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof, Queensland University of Technology with the Translational Genomics Research Institute (US), 9 February 2016
  • US Patent 9,247,766, Angiogenin-enriched milk fractions, Murray Goulburn Co-Operative with Agriculture Victoria Services, 2 February 2016
  • US Patent 9,243,066, Use of M-CSF antibodies in the treatment of osteoarthritis or pain, University of Melbourne with MorphoSys (Germany), 26 January 2016
  • US Patent 9,243,061, Osteoarthritis treatment, University of Melbourne, 26 January 2016
  • US Patent 9,242,007, Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells,  EnGeneIC, 26 January 2016
  • US Patent 9,241,952, Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin, ​OzStar Therapeutics, 26 January 2016
  • US Patent 9,241,883, Ionic complexes, University of Melbourne, 26 January 2016
  • US Patent 9,239,904, Computer systems for treating diseases, Biotempus, 19 January 2016
  • US Patent 9,238,644, VEGFR3 inhibitors, Cancer Therapeutics CRC, 19 January 2016
  • US Patent 9,238,054, Treatment of kidney fibrosis with VIP fragments, Vectus Biosystems (ASX: VBS), 19 January 2016
  • US Patent 9,238,001, Delivery system for remote treatment of an animal, Smartvet Pty Ltd, 19 January 2016
  • US Patent 9,234,019, Modified Cpn10 and PRR signalling, Invion (ASX: IVX), 12 January 2016
  • US Patent 9,226,939, Histone inhibition, Australian National University, 5 January 2016

New Zealand applications

Here are the 16 US patents relevant to New Zealand's Life Sciences sector that were granted in 2016, for an issuance rate of 0.3 applications per week:​
  • US Patent 9,522,159, Treatment and prevention of P. aeruginosainfections using coformycin analogs, Viclink (Victoria University of Wellington, 20 December 2016
  • US Patent 9,469,675, Anti-inflammatory proteins and methods of preparation and use thereof, ManukaMed, 18 October 2016
  • US Patent 9,452,155, Injectable antibiotic formulations and their methods of use, Bayer New Zealand, 27 September 2016
  • US Patent 9,415,061, Compositions and methods for treatment of neoplastic disease, Innate Immunotherapeutics (ASX: IIL), 16 August 2016
  • US Patent 9,375,413, Methods of reducing milk somatic cell count, AgResearch Ltd, 28 June 2016
  • US Patent 9,359,392, Dendrimer scaffolds for pharmaceutical use, Viclink (Victoria University of Wellington), 28 June 2016
  • US Patent 9,353,349, Synthetic membrane anchors, Kode Biotech, 31 May 2016
  • US Patent 9,339,479, Dosage forms and related therapies, PhilERA (Professor Garth Cooper), 17 May 2016
  • US Patent 9,320,781, Dietary supplement for managing gut health, Vital Foods, 26 April 2016
  • US Patent 9,315,587, Oligosaccharide compounds, Viclink (Victoria University of Wellington) with University of Liverpool (UK)​, 19 April 2016
  • US Patent 9,314,505, Combination treatments and compositions for wound healing comprising viral VEGF, Otago Innovation (University of Otago), 19 April 2016
  • US Patent 9,314,478, Method of making an anhydrous, fat soluble, chewable drug delivery formulation, Argenta, 19 April 2016
  • US Patent 9,296,789, Vaccines and vaccine components for inhibition of microbial cells, Pastoral Greenhouse Gas Research, 29 March 2016
  • US Patent 9,290,501, Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase,  Viclink (Victoria University of Wellington) with Albert Einstein College of Medicine​ (US), 22 March 2016
  • US Patent 9,255,109, Fungicidal compounds and methods of their use,  Auckland UniServices (University of Auckland), 9 March 2016
  • US Patent 9,226,968, Carbohydrate-lipid constructs and their use in preventing or treating viral infection, Kode Biotech, 5 January 2016

Copyright © 2017 NDF Research
Proudly powered by Weebly
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog